Chemomab Therapeutics announces new scientific presentation on nebokitug

Chemomab Therapeutics (CMMB) announced a new scientific presentation that further confirms the potential of nebokitug as a novel treatment for systemic sclerosis, SSc. The data will be presented at the 8th International Congress on Controversies in Rheumatology and Autoimmunity, CORA 2025, on March 8, 2025, in Venice, Italy. “This new data adds to the extensive body of preclinical evidence that CCL24 is a key driver of the skin, lung and vascular manifestations of this disabling condition that lacks disease-modifying therapies,” said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. “These results further reinforce our belief, based on multiple preclinical and patient sample studies and the positive results from our Phase 2 PSC trial, that nebokitug has substantial potential as a treatment for SSc. Chemomab has an open U.S. IND for a Phase 2 trial of nebokitug in SSc.”